<?xml version="1.0" encoding="UTF-8"?>
<p id="p0205">Potential drug candidates for COVID-19 therapy are continuously substituted and changed, similar to basketball players in the last minutes of the final game to save the championship. Remdesivir, the most awaited and most promising candidate, has been fervently supported by doctors and politicians as a potential cure for COVID-19 [
 <xref rid="bib129" ref-type="bibr">129</xref>] but appears to be inefficient according to the first randomized trial (158 patients) in China on patients with severe COVID-19 symptoms [
 <xref rid="bib130" ref-type="bibr">130</xref>]. In addition, it was found that a high dosage of remdesivir may induce testicular toxicity and result in deterioration of sperm parameters in mice [
 <xref rid="bib131" ref-type="bibr">131</xref>].
</p>
